Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)
ArchivedNational Institutes of Health
Description
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>grantsinfo@nih.gov
grantsinfo@nih.gov
- PostedApr 6, 2021
- ClosesOct 20, 2021
- Award ceiling$500,000
- CFDA93.847
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro